29786-38-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Bromophenyl)-cyclobutanecarbonitrile serves as a key building block in the organic synthesis of various pharmaceutical products. Its unique structure and functional groups make it a valuable intermediate for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 1-(3-Bromophenyl)-cyclobutanecarbonitrile is utilized as a starting material for the synthesis of a range of agrochemicals. Its properties allow for the creation of compounds that can be used in pest control and crop protection, contributing to enhanced agricultural productivity.
Used in Organic Synthesis:
1-(3-Bromophenyl)-cyclobutanecarbonitrile is employed as a versatile intermediate in organic synthesis for the preparation of diverse organic compounds. Its cyclobutane ring and functional groups facilitate the construction of complex molecular architectures, which are essential in various chemical and material science applications.

Upstream product

• 31938-07-5 (3-bromophenyl)acetonitrile 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 1160499-05-7 C₁₇H₁₄N₄ 
• 1160501-51-8 (1-(3-(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)cyclobutyl)methanamine 
• 1160498-80-5 (1-(3-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)cyclobutyl)methanamine trifluoroacetate 
• 1195172-98-5 1-(1-(3-bromophenyl)cyclobutyl)-3-(4-(2-methylpyridin-4-yl)phenyl)urea 
• 1195178-54-1 1-(3-bromophenyl)cyclobutanecarbonyl azide 
• 926261-31-6 1-(3-bromophenyl)cyclobutanecarboxylic acid 
• 29786-30-9 (<1-(m-Bromophenyl)cyclobutyl>carbonyl)carbamsaeureethylester 
• 29786-18-3 (<1-(m-Bromophenyl)cyclobutyl>carbonyl)carbamsaeuremethylester 
• 29770-35-2 (<1-(m-Bromophenyl)-cyclobutyl>-carbonyl)-harnstoff 
• 29786-59-2 <1-(m-Bromophenyl)-cyclobutyl>-carbonylisocyanat 
• 29786-48-9 1-(3-bromophenyl)cyclobutane-1-carboxamide 

Relevant academic research and scientific papers

Synthesis method of arylcyclobutane compound

The present invention discloses a method for synthesizing an arylcyclobutane compound to 1eq phenylacetonitrile and 1.1eq 1-bromo-3-chloropropane as raw material, N,N- dimethylacetamide as a solvent, plus 2.5eq sodium hydride, under the protection of iner

Discovery of selective, orally bioavailable pyrazolopyridine inhibitors of protein kinase cθ (pkcθ) that ameliorate symptoms of experimental autoimmune encephalomyelitis

PKCθ plays an important role in T cell biology and is a validated target for a number of disease states. A series of potent and selective PKCθ inhibitors were designed and synthesized starting from a HTS hit compound. Cell activity, while initially a challenge to achieve, was built into the series by transforming the nitrile unit of the scaffold into a primary amine, the latter predicted to form a new hydrogen bond to Asp508 near the entrance of the ATP binding site of PKCθ. Significant improvements in physiochemical parameters were observed on introduction of an oxetane group proximal to a primary amine leading to compound 22, which demonstrated a reduction of symptoms in a mouse model of multiple sclerosis.

Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)

N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with 1a reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.

UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS

The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.